Patents by Inventor Karin Kristina Amundson

Karin Kristina Amundson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human monoclonal antibodies to activin receptor-like kinase-1
    Patent number: 9221915
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like, kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: December 29, 2015
    Assignees: Pfizer Inc., Amgen Fremont Inc.
    Inventors: Shelley Sims Belouski, Sirid-Aimée Kellerman, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
  • HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR-LIKE KINASE-1
    Publication number: 20120052074
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like, kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Application
    Filed: October 26, 2011
    Publication date: March 1, 2012
    Applicants: PFIZER INC., AMGEN FREMONT INC.
    Inventors: Shelley Sims Belouski, Sirid-Aimée Kellerman, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
  • Human monoclonal antibodies to activin receptor-like kinase-1
    Patent number: 8080646
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: December 20, 2011
    Assignees: Amgen Fremont, Inc., Pfizer Inc.
    Inventors: Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Shelly Sims Belouski, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, Sirid Aimee Kellerman, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
  • HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR-LIKE KINASE-1
    Publication number: 20100197005
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Application
    Filed: March 12, 2009
    Publication date: August 5, 2010
    Applicants: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Shelley Sims Belouski, Sirid-Aimee Kellermann, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
  • Human monoclonal antibodies to activin receptor-like kinase-1
    Patent number: 7537762
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: May 26, 2009
    Assignees: Amgen Fremont, Inc., Pfizer Inc.
    Inventors: Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Shelley Sims Belouski, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, Sirid Aimee Kellerman, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang